Subscribe
istock-669281432_nataliaderiabina
NataliaDeriabina / iStockphoto.com
22 November 2017Europe

Prenatal test infringes Illumina patents, rules English High Court

A prenatal test sold by molecular diagnostics company Premaitha Health infringes patents owned by genetic sequencing firm Illumina, a UK court has ruled.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Illumina files for patent infringement over prenatal test
8 September 2017   Genetic sequencing company Illumina has filed a patent infringement suit against Premaitha Health, a molecular diagnostics company, in the English High Court.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Europe
Illumina files for patent infringement over prenatal test
8 September 2017   Genetic sequencing company Illumina has filed a patent infringement suit against Premaitha Health, a molecular diagnostics company, in the English High Court.

More on this story

Europe
Illumina files for patent infringement over prenatal test
8 September 2017   Genetic sequencing company Illumina has filed a patent infringement suit against Premaitha Health, a molecular diagnostics company, in the English High Court.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott